期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

p57^(K1P2)和PHLDA2蛋白表达对葡萄胎的诊断意义 被引量：2

The value of p57^(K1P2) and PHLDA2 in the differential diagnosis of placental hydropic diseases
下载PDF
导出
摘要 目的研究母源表达的印记基因p57K1P2和PHLDA2(IPL/TSSC3)蛋白表达对葡萄胎的辅助诊断意义。方法收集北京协和医院刮宫组织存档的石蜡包埋标本,其中病理组织学诊断完全性葡萄胎(completehydatidiformmole,CHM)13例,部分性葡萄胎(partialhydatidiformmole,PHM)16例。全部病例行流式细胞术DNA倍体分析,采用免疫组化二步法检测p57K1P2及PHLDA2在病理组织中表达。结果29例病例DNA倍体分析:二倍体15例,三倍体13例,四倍体1例,诊断为CHM15例,PHM14例,病理诊断的符合率为86.2%。部分性葡萄胎p57K1P2和PHLDA2绒毛滋养细胞层免疫组织化学全部阳性(100%,14/14)。PHLDA2染色阳性位于胞质和胞膜,表达为强阳性。p57K1P2染色阳性位于胞核,表达为强阳性。所有完全型葡萄胎绒毛滋养细胞层p57K1P2和PHLDA2免疫组织化学均阴性(100%,15/15)。结论p57K1P2和PHLDA2可能是鉴别CHM和非CHM的标志物,两者免疫组化学阴性可能是CHM的可靠标志物,但有待扩大样本验证。 Objective To investigate the value of combined use of p57K1P2 and PHLDA2 immunohistochemistry and flow cytometry in the difierential diagnosis of placental hydropic diseases.Methods Specimens of 29 cases of mole pregnancy, formerly diagnosed as complete hydatidiform moles（CHM,n=13）,and partial hydatidiform moles （PHMn=16）, were reviewed by a senior pathologist.p57K1P2 and PHLDA2 immunohistochemical staining and flow cytometry DNA ploidy analysis were performed in all 29 cases.Results Flow cytometry in all 29 molar cases suggested that 14 cases were triploidy or tetraploid （means these cases are PHM） and 15 cases were diploidy （means these cases are CHM）.All flow cytometrically confirmed partial moles were both p57K1P2 and PHLDA2 positive.There was strong PHLDA2 staining of the cytoplasm in virtually all cells of the villous cytotrophoblast, while p57K1P2 was localized to the nucleus in a subset of those cells. All flow cytometrically showed that complete moles cases were both p57K1P2 and PHLDA2 negative.Conclusion Immunohistochemistry for p57K1P2 and PHLDA2 may be serves as a practical and reliable diagnostic marker for the diagnosis of complete mole from partial mole.
作者 方芳 万希润 向阳 冯风芝 任彤
机构地区 北京中国协和医科大学
出处 《中国妇产科临床杂志》 2012年第1期43-45,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 葡萄胎 免疫组织化学 流式细胞分析 p57K1P2 mole pregnancy immunohistochemistry flow cytometry p57K1P2
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Fukunaga M, Katabuchi H, Nagasaka T, et al. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole AmJ SurgPathol, 2005, 29: 942-947.
  • 2Genest DR. Partial hydatidiform mole: clinicopathological features, diagnosis, ploidy and molecular studies, and gold standards for diagnosis. Int J Gynecol Pathol, 2001, 20: 315 - 322.
  • 3Kerkmeijer LG, Massuger LF, Ten Kate--Booij MJ, et al. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. Obstet Gynecol, 2009, 113.. 326-331.
  • 4Fowler DJ, Lindsay I, Seckl MJ, et al. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: Experience of more than 1000 cases from a regional center. Ultrasound Obstet Gynecol, 2006, 27: 56-60.
  • 5Chilosi M, Piazzola E, Lestani M, et al. Differential expression of p57xlP2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest, 1998, 78: 269-276.
  • 6Frank D, Fortino W, Clark L, et al. Placental overgrowth in mice lacking the imprinted gene Ipl. Proc Natl Acad Sci USA, 2002, 99: 7490-7495.
  • 7Hedley DW, Friedlander ML, Taylor IW, et al. A method for analysis of cellular DNA content of paraffin embedded pathological material using flow cytometry. J Histochem Cytochem, 1983, 31: 1333.
  • 8Noriyoshi I, Yuji H, Yusuke T, et al. Reevaluation of the histological criteria for complete hydatidiform mole: Comparison with the immunohistochemical diagnosis using p57Kip2 and CD34. Biomedical Research, 2009, 30:141 - 147.
  • 9Kato H, Wake N. Differential diagnosis between complete and partial mole using a TSSC3 antibody: correlation with DNA polymorphic marker analysis. Reprod Med, 2006, 51: 861-867.
  • 10侯进琳,万希润,向阳,戚庆伟,杨秀玉.葡萄胎临床表现的新特点:113例葡萄胎临床分析[J].生殖医学杂志,2007,16(6):404-408. 被引量：15

二级参考文献10

  • 1Soto-Wright V,Bernstein M,Goldstein DP, et al , The changing clinical presentation of complete molar pregnancy [J], Obstet Gynecol, 1995,86 (5) :775-779.
  • 2Kim DS, Moon H, Kim KT, Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole[J], Obstet Gynecol, 1986, 67 (4) :690-694.
  • 3Kashimura Y, Kashimura M, Sugimori H, et al. Prophylactic chemotherapy for hydatidiform moles. Five to 15 years follow up[J]. Cancer, 1986,58 (3) : 624-629.
  • 4Soper, JT. Gestational trophoblastic disease[J]. Obstet Gynecol, 2006,108(1) :176-187.
  • 5Lurain JR, Brewer JI, Torok EE, et al. Natural history of hydatidiform mole after primary evacuation[J]. Am J Obstet Gynecol,1983,145(5) :591-595.
  • 6Bagshawe KD, Wilson H, Dublon P, et al. Follow up after hydatidiform mole: studies using radioimmunoassays for urinary human ehorionie gonadotropin (hCG) [J], J Obstet Gyneeol Br Commonw, 1973,80 (5) : 461-468.
  • 7Morrow CP, Postmolar trophoblastie disease: Diagnosis, management and prognosis[J], Clin Obstet Gynaecol , 1984, 27(1) :211-220.
  • 8Hancock BW, Tidy JA. Current management of molar pregnancy[J]. J Reprod Med,2002 ,47(5):347-354.
  • 9Kohorn EI, The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment [J], Intl J Gynecol Cancer, 2001, (1) :73-77.
  • 10Hui P, Martel M,Parkash V. Gestational trophoblastic diseases recent advances in histopathologic diagnosis and related genetic aspects[J]. Adv Anat Pathol, 2005,12(3): 116-125.

共引文献14

同被引文献37

  • 1Chilosi M,Piazzola E,Lestani M,et al.Differential expression of P57,amaternally imprinted cdk inhibitor,in normal human placenta and ges-tational traphoblastic disease[J].Lab Invest, 1998,78:269-276.
  • 2Genest DR. Partial hydatidiform mole: clinicopathological features,differential diagnosis,ploidy and molecular studies, and gold stan-dards for diagnosis[J]. Int J Gynecol Pathol,2001,20(4):315-322.
  • 3Fukunaga M. Immunohistochemical characterization of p57(KIP2) ex-pression in early hydatidiform moles [J]. Hum pathol, 2002,33(12):1188-1192.
  • 4Merchant SH, Amin MB, Viswnanatha DS, et al. p57 (KIP2) immuno-histochemistry in early molar pregnancies: emphasis on its comple-mentary role in the differential diagnosis of hydropic abortuses [J].Hum pathol, 2005,36(2):180-186.
  • 5Jun S-Y,Ro JY,Kim K-R. p57 (KIP2) is useful in the classificationand differential diagnosis of complete and partial hydatidiform moles[J]. Histopathology, 2003,43(1):17-25.
  • 6Jun SY, Ro JY, Kim KR, et al. Genetic origin and imprinting in hyda-tidi form moles. Comparison between DNA polymorphism analysisand immunoreactivity of p57 (KIP2)[J]. J Reprod Med, 2005,50(5):307-312.
  • 7Fowler DJ,Lindsay I,Seckl MJ,et al.Routne pre-evacuation ultrasounddiagnosis of hydatidiform mole:Experience of more than 1000 casesfrom a regional center[J]. Ultrasound Obstet Gynecol, 2006,27:56-60.
  • 8Noriyoshi I, Yuji H, Yusuke T, et al. Re-evaluation of the histologicalcriteria for complete hydatidiform male: Comparison with the im-munohistochemical diagnosis using P57 and CD34 [J]. BiomedicalResearch, 2009,30:141-147.
  • 9McConnell TG, Murphy KM, Hafez M, et al. Diagnosis and subclas-sification of hydatidiform moles using p57immunohistochemistry andmolecular genotypingrvalidation and prospective analysis in routineand consulation practice settings with development of an algorithmicapproach[J]. Am J SurgPathol, 2009,33(6):805-817.
  • 10Merchant SH, Amin MB, Viswnanatha DS, et al. p57(KIP2)immuno-histochemistry in early molar pregnancies: emphasis on its comple-mentary role in the differential diagnosis of hydropic abortuses [J].Hum pathol, 2005, 36(2): 180-186.

引证文献2

二级引证文献5

中国妇产科临床杂志
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部